NCT04983173 - INTEnsity of ovariaN Stimulation and Embryo Quality | Biotech Hunter

Enrollment

110

Participants

Timeline

Start Date

November 23, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions

Infertility

Interventions

DRUG

Ovarian Stimulation with CC+rFSH

: CC 50 mg/day (Omifin®) + rFSH 150 IU (Ovaleap®) GnRH antagonist: ganirelix 0.25 mg (Orgalutran®) Recombinant human chorionic gonadotropin (rhCG) 250 μg (Ovitrelle®) micronized progesterone 200 mg 3id (Utrogestan®)

DRUG

Ovarian Stimulation with rFSH

rFSH 300 IU rFSH (Ovaleap®) GnRH antagonist: ganirelix 0.25 mg (Orgalutran®) Recombinant human chorionic gonadotropin (rhCG) 250 μg (Ovitrelle®) micronized progesterone 200 mg 3id (Utrogestan®)

Trial Locations (1)

08028

RECRUITING

Salud de la Mujer Dexeus, Barcelona

All Listed Sponsors

lead

Fundación Santiago Dexeus Font

OTHER